Related Experiment Video

Updated: Jul 23, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Real world outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma

Omar Elghawy1, Adam Barsouk1, Jessica Xu1

  • 1Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

European Thyroid Journal
|November 1, 2024
PubMed
Abstract

Insights

Cabozantinib shows promise for poorly differentiated thyroid carcinoma (PDTC), a rare and aggressive cancer. This study found it effective and well-tolerated, suggesting a potential new treatment option for PDTC patients.

Area of Science:

  • Oncology
  • Head and Neck Cancer Research
  • Thyroid Cancer Therapeutics

Background:

  • Poorly differentiated thyroid carcinomas (PDTCs) are aggressive malignancies with limited treatment options.
  • Current systemic therapy for PDTC often extrapolates from differentiated thyroid cancer (DTC) treatments.
  • Cabozantinib is an approved multi-kinase inhibitor (MKI) for DTC, but its use in PDTC is not well-documented.

Purpose of the Study:

  • To evaluate the safety and efficacy of cabozantinib in patients with PDTC.
  • To assess clinical outcomes including progression-free survival (PFS) and overall survival (OS) in PDTC patients treated with cabozantinib.

Main Methods:

  • Retrospective analysis of seven PDTC patients treated with cabozantinib.
  • Data collection included demographics, disease characteristics, treatment history, toxicity, and outcomes.
  • Kaplan-Meier methodology was used to estimate median PFS and OS.

Main Results:

  • Partial response was observed in 57% of patients, with 29% achieving stable disease.
  • Median PFS was 12.9 months and median OS was 14.21 months.
  • Most adverse events were low grade, and 29% of patients were alive at follow-up.

Conclusions:

  • Cabozantinib demonstrates efficacy and acceptable tolerability in PDTC patients.
  • Further prospective studies are warranted to confirm cabozantinib's role in PDTC treatment.
  • Investigating cabozantinib in combination with other therapies, like checkpoint inhibitors, is recommended.
Keywords:
Poorly differentiated thyroid cancercabozantiniblenvatinibsorafenibthyroid cancer

More Related Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...